Intrahepatic cholestasis and phospholipidosis associated with the use of trimethoprim‐sulfamethoxazole

Santiago J. Muñoz, Antonino Martinez-Hernandez, Willis C. Maddrey

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


Although liver injury after administration of the trimethoprim‐sulfamethoxazole combination is rare, hepatocellular necrosis and cholestasis have developed in a few cases. We describe a patient who developed a severe, prolonged cholestatic reaction after trimethoprim‐sulfamethoxazole administration. The findings from serial liver biopsy samples showed characteristic abnormalities of phospholipidosis that have not been previously described for trimethoprimsulfamethoxazole–related hepatic injury. The most prominent finding on electron microscopic evaluation of the liver was the presence of prominent hepatocyte lysosomal inclusions characterized by concentric arrangements of membranous and lamellated structures. The patient improved after several courses of exchange plasmapheresis, which may have assisted in the removal of toxic drug‐lipid complexes. The pathogenesis of this acquired secondary phospholipidosis is unknown. Possible mechanisms include generation of highly lipid‐soluble metabolites and inhibition of the lysosomal enzyme phospholipase A1. (HEPATOLOGY 1990; 12:342–347).

Original languageEnglish (US)
Pages (from-to)342-347
Number of pages6
Issue number2
StatePublished - Aug 1990

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Intrahepatic cholestasis and phospholipidosis associated with the use of trimethoprim‐sulfamethoxazole'. Together they form a unique fingerprint.

Cite this